Feature | May 08, 2015

PET Scan Could Remove Need for Radiotherapy for Cured Patients

U.K. study finds follow-up radiotherapy reduces recurrence rate only marginally while adding side effects

University of Manchester, PET, radiotherapy, cured patients, Hodgkin lymphoma

May 8, 2015 — A U.K. National Cancer Research Institute trial has suggested that in patients with early stage Hodgkin lymphoma, the late effects of radiotherapy could be reduced by using a scan to determine those who actually need it. The trial was led from The University of Manchester and the Christie NHS Foundation Trust.

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy. Hodgkin lymphoma is a cancer that develops in the lymphatic system, which is a network of vessels and glands spread throughout the body. Around 1,900 people a year, many of whom are teenagers and young adults, are diagnosed in the U.K.

The current standard treatment is for all Hodgkin lymphoma patients to receive chemotherapy, followed by radiotherapy. However, this radiotherapy comes with undesirable late effects, such as cardiovascular disease and other cancers — despite the fact that they have already been cured of Hodgkin lymphoma.

The 602 patients who agreed to take part in the 'RAPID' trial had a PET scan performed after their chemotherapy. Patients who tested positive received radiotherapy. Those who tested negative were divided into two groups — one group of 211 patients received no further treatment, while the other group of 209 had the standard radiotherapy.

After three years of regular check-ups, the proportion of patients who were alive and free of disease was 94.6 percent in the radiotherapy group, and 90.8 percent in the group which hadn't received further treatment.

Lead researcher, Prof. John Radford, is based at The University of Manchester's Institute of Cancer Sciences and the Christie NHS Foundation Trust. He said: "This research is an important step forward. The results of RAPID show that in early stage Hodgkin lymphoma, radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured."

Despite the findings from this study the researchers stress that a longer follow-up period is needed in order to determine whether this approach will ultimately lead to fewer late side-effects and improved overall survival.

The research was funded by Leukemia & Lymphoma Research. Matt Kaiser, M.D., head of research at the charity, said: "This groundbreaking clinical trial shows that, by using scans to predict an individual's risk of relapse, many patients can remain disease-free with just chemotherapy alone. Radiotherapy can cause a range of long-term problems like heart disease and hard-to-treat second cancers. As many Hodgkin lymphoma patients are relatively young, it is particularly important to avoid using intensive treatment when it is unnecessary."

For more information: www.manchester.ac.uk

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...